

Form PTO-1419  
(REV. 8-83)



U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,892

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 1614

**U. S. PATENT DOCUMENTS**

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Y.C.J.	4,122,193	Scherm et al.	October 24, 1978		
Y.C.J.	4,233,229	Chakrabarti	November 11, 1980		
Y.C.J.	4,355,043	Durlach	October 19, 1982		
Y.C.J.	5,061,703	Bormann et al.	October 29, 1991		
Y.C.J.	5,262,162	Bormann et al.	November 16, 1993		
Y.C.J.	5,382,601	Nürnberg et al.	January 17, 1995		
Y.C.J.	5,455,279	Lipton	October 3, 1995		
Y.C.J.	5,602,150	Lidsky	February 11, 1997		
Y.C.J.	5,614,560	Lipton	March 25, 1997		

RECEIVED  
 OCT 03 2001  
 TECH CENTER 1500/2900

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

Examiner's  
Initials

**OTHER DOCUMENTS**  
(Including Author, Title, Date, Pertinent Pages, Etc.)

Y.C.J.	Alexander, et al., "Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment", Brit. F. Psychiat. 133: 143-49, 1978.
Y.C.J.	Ananth, et al., "Meige's Syndrome Associated with Neuroleptic Treatment", Am J. Psychiatry 145:4, April, 1988.

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,892

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 16

RECEIVED  
OCT 03 2001  
TECH CENTER 1600/2800

Y.C.I	Andrew, "Clinical Relationship of Extrapyrarnidal Symptoms and Tardive Dyskinesia", Can. J. Psych., 39:576-580, 1994.
Y.C.I	Andreassen, et al., "Tardive Dyskinesia: Behavioral Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis", Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994
Y.C.I	Andreassen, et al., "Inhibition by Memantine of the Development of Persistent Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats", British Journal of Pharmacology 119: 751-757, 1996.
Y.C.I	Arthurs, et al., "Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin", Can J. Ophthalmol., 22:1, 1987.
Y.C.I	Athanassenas, et al., "Serum Calcium and Magnesium Levels in Chronic Schizophrenics", Journal of Clinical Psychopharmacology, 3:4, August, 1983
Y.C.I	Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyrarnidal Symptoms", Can. J. Psych., 39:74-84, 1994.
Y.C.I	Boumans et al., "Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?", Schizo Bull, 20:339-344, 1994.
Y.C.I	Britton, et al., "Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats" Life Sciences, 60:20, 1729-1740, 1997.
Y.C.I	Büchel et al., "Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing", Psychopharmacology-Berl, 117:162-165, 1995.
Y.C.I	Casey, D. "Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome", Neurology, 30:690-695, July, 1980.
Y.C.I	Cassady, et al., "Neuroleptic Induced Movement Disorders", Cambridge, England: Cambridge University Press, 1997, pp454-469.
Y.C.I	Chabenat, et al., " Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAergic Compound, Calcium Acetylthiomotaurinate", Methods Find Exp Clin Pharmacol, 10:311-7, 1988 May.
Y.C.I	Chakos et al., "Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia", Arch Gen Psychiatry, 53:313-319, 1996.
Y.C.I	Chappell, et al., "Future Therapies of Tourette Syndrome", Neurologic Clinics of North America, 15:2, May, 1997.
	Chen, et al., "Focal Dystonia and Repetitive Motion Disorders", Clinical Orthopaedics and Related Research, 351: 102-106.

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,897

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 16

RECEIVED  
OCT 03 2001  
TECHNICAL CENTER 1600 2900

Y.C.I	Dabiri, et al., "Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia", Am J. Psychiatry 151:6, June 1994.
Y.C.I	Decker et al., "Amantadine Hydrochloride Treatment of Tardive Dyskinesia", October 7, New England J. Med, 285:860, 1971.
Y.C.I	Delfs et al., "Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in an Animal Model of Tardive Dyskinesia", Exp. Neurol, 133:175-188, 1995.
Y.C.I	De Mattos, et al., "Distonias Aspectos Clinicose E Terapeuticos EM 64 Pacientes", Arq. Neuropsiquiatr, 54:30-36, 1996.
Y.C.I	Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro", Arzneimittelforschung, 45:1-5, 1995.
Y.C.I	Durlach, et al., "Magnesium Status and Ageing: An Update", Magnesium Research 11:25-42, 1997.
Y.C.I	Egan M.F., et al., "Treatment of Tardive Dyskinesia" Schizophr Bull, 23(4):583-609 1997
Y.C.I	Elston, J. "The Management of Blepharospasm and Hemifacial Spasm", J. Neurol 239:5-8, 1992.
Y.C.I	Ema, et al., "Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium", Alcohol, 15:95-103, 1998.
Y.C.I	Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 198:215-217, 1991.
Y.C.I	Esper, et al., "Adult-Onset Focal Dystonias: Presentation and Treatment Options", Tennessee Medicine, 18-20, January, 1997.
Y.C.I	Fariello, R.G. et al., "Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects Froom The Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid." Neurology, 32:241-5, March, 1982.
Y.C.I	Galardi, et al., "Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis", Acta Neurol Scand 94:172-176, 1996.
	<del>Greensmith, et al., "Magnesium Ions Reduce Motoneuron Death Following Nerve Injury or Exposure to N-Methyl-D-Aspartate In The Developing Rat"</del>
Y.C.I	Gao et al., "Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats", J. Neural Transmission, 95:63-69, 1994.
Y.C.I	Gardos, et al., "The Treatment of Tardive Dyskinesias", Psychopharmacology, 1503-1511, 1995.

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,892

RECEIVED  
OCT 03 2001

TECH CENTER 10022900

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 16

Gullestad, et al., "Magnesium Status in Healthy Free Living Elderly Norwegians", Journal of the American College of Nutrition, 13:145-50.

*/Y.C./* Hallett, M. "The Neurophysiology of Dystonia", Arch Neurol, 55: May, 1998

*/Y.C./* Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia", Clin. Neuropharmacol, 19:390-398, 1996.

*/Y.C./* Holds, et al., "Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm", AFP, 43(6): 2113-2120, June, 1991.

*/Y.C./* Imamura et al., "Improved Presevation with Amantadine", Abstract, No-To-Shinkei, 46:556-562, 1994.

*/Y.C./* Jacoby, et al., "Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and in Vivo", Investigative Ophthalmology & Visual Science, 31:569-576, March, 1990.

*/Y.C./* Jankovic, J. "Treatment of Hyperkinetic Movement Disorders with Tetrabenazine: A Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982.

*/Y.C./* Jankovic, J. "Blepharospasm and Orofacial - Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients", Ann Neurol 13:402-411, 1983.

*/Y.C./* Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-765, 1995.

*/Y.C./* Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur. J. Pharmacol, 219:451-454, 1992.

*/Y.C./* Kirov, et al., "Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms", Neuropsychobiology 30:73-78, 1994.

*/Y.C./* Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists", Abstract, Nervenarzt, 67:77-82, 1996.

~~Krieglstein, et al., "Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage"~~

*/Y.C./* Kurata, et al., "Meige's Syndrome During Long-Term Neuroleptic Treatment", The Japanese Journal of Psychiatry 43: 627-631, 1989.

*/Y.C./* Kurlan, R. "Treatment of Tics", Neurologic Clinics of North America, 15:2, 403-409, May, 1997.

*/Y.C./* Lam et al., "Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dis, 182:113-114, 1994.

*/Y.C./* Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,892

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

SEP 2 8 2001

(Use several sheets if necessary)

Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 161

TECH CENTER 161002900

Oct 03 2001

RECEIVED

<i>(Y.C.)</i>	Leckman, et al., "Tic Disorders", The Psychiatric Clinics of North America, 20:4 839-861, December, 1997.
<i>(Y.C.)</i>	Lichter, et al., "Predictors of Clonidine Response in Tourette Syndrome: Implications and Inferences", Journal of Child Neurology 11:93-97, March, 1996.
<i>(Y.C.)</i>	Lipski, et al., "A Study of Nutritional Deficits of Long-Stay Geriatric Patients, Age and Ageing 22:244-255, 1993.
<i>(Y.C.)</i>	Lohr et al., "A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia", J. Clin. Psychiatry, 57:167-173, 1996.
	<del>Lombardini, John B., "Opposite Effects of 2-Aminoethanesulfonic Acid (Taurine) and Aminomethanesulfonic Acid on Calcium Ion Uptake in Rat Retinal Preparations"</del>
<i>(Y.C.)</i>	Martin, et al., "Comparison of Inorganic Elements from Autopsy Tissue of Young and Elderly Subjects", J. Trace Elem. Electrolytes Health Dis., 5:203-211, 1991.
<i>(Y.C.)</i>	Mauriello, et al., "Treatment Selections of 239 Patients with Blepharospasm and Meige Syndrome over 11 Years", Br. J. Ophthalmol., 80(12):1073-1076, December, 1996
<i>(Y.C.)</i>	Mauriello, et al., "Treatment Choices of 119 Patients with Hemifacial Spasm over 11 Years", Clinical Neurology and Neurosurgery, 98: 213-216, August 1996.
<i>(Y.C.)</i>	Meshul, et al., "Correlation of Vacuous Chewing Movements with Morphological Changes in Rats Following 1-Year Treatment with Haloperidol", Psychopharmacology 125:238-247, 1996
	<del>Micheli, et al., "Continuous Dopaminergic Stimulation in Cranial Dystonia" Clinical Neuropharmacology, 11:3, 241-249</del>
<i>(Y.C.)</i>	Muller et al., "Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia", Pharmacopsychiatry, 28:113-124, 1995.
<i>(Y.C.)</i>	Pahl et al., "Positron-Emission Tomography in Tardive Dyskinesia", J. Neuropsych Clin. Neurosci, 7:457-465, 1995.
<i>(Y.C.)</i>	Panula-Lehto E. et al., "Effects of Taurine, Homotaurine and GABA on Hypothalamic and Striatal dopamine Metabolism." Naunyn Schmiedebergs Arch Pharmacol, 346:57-62, July, 1992
<i>(Y.C.)</i>	Perlmutter, et al., "Decreased [ <sup>18</sup> F] Spiperone Binding in Putamen Idiopathic Focal Dystonia", The Journal of Neuroscience, 17:843-850, 1997.
<i>(Y.C.)</i>	Ploceniak, "Bruxisme et magnesium, mon experience clinique depuis 1980" Communications Libres, 91, supplII, 1990

Form PTO-1449  
(REV. 8-83)


U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,892

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

*(Use several sheets if necessary)*



Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 16

RECEIVED  
OCT 03 2001  
TECH CENTER 1600/2900

/Y.C./	Raja, "The Treatment of Tardive Dyskinesia", Abstract, Schweiz Arch Neurol Psychiatr, 47: 1996.
/Y.C./	Ransmayr, et al., "Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm", Clinical Neuropharmacology, 11:68-76, 1988.
/Y.C./	Rouhani, S. et al., "Effects of Muscimol or Homotaurine on Sleep-Wake States in Alcohol-dependent rats during Withdrawal." Pharmacol Biochem Behav, 59:955-60, April, 1998
/Y.C./	Sachdev, "Blinking-blepharospasm after long-term neuroleptic treatment", The Medical Journal of Australia, 150:341-343, March 20, 1989
/Y.C./	Sachdev et al., "Negative Symptoms, Cognitive Dysfunction, Tardive Akathisia and Tardive Dyskinesia", Acta Psychiatr Scand, 93:451-459, 1996.
/Y.C./	Sanberg, et al., "Nicotine for the Treatment of Tourette's Syndrome", Pharmacol. Ther. Vol. 74, 21-25, 1997.
/Y.C./	Sandyk, "Blepharospasm - Successful Treatment with Baclofen and Sodium Valproate", SA Medical Journal, 64:3 December, 1993.
/Y.C./	Sano et al., "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", The New England Journal of Medicine, Vol. 336, No. 17, pp. 1216-1247, April 24, 1997.
/Y.C./	Scahill, et al., "Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study," Journal of Child and Adolescent Psychopharmacology, 7:75-85, 1997.
/Y.C./	Schulz et al., "Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases", Neuroscience, 71:1043-1048, 1996.
/Y.C./	Shane, et al., "Magnesium Deficiency in Alcohol Addiction and Withdrawal", Magnes Trace Elem, 92:263-268, 1991.
/Y.C./	Silver et al., "No Difference in the Effect of Biperiden and Amantadine on Parkinsonian and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo-Controlled Study in Medicated Chronic Schizophrenic Patients", Abstract, J. Clin. Psychiatry, 56:167-170, 1995.
/Y.C./	Silver, et al., "Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome, J. Am. Chil. Adolesc. Psychiatry, 35:12, December, 1996
/Y.C./	Stoessl, "Effects of Ethanol in a Putative Rodent Model of Tardive Dyskinesia", Pharmacol Biochem Behav, 54:541-546, 1996.

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
0264724-0007

In re Application No.  
09/193,892

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:  
November 18, 1998

Group: 12023900

RECEIVED  
OCT 03 2001  
TECH CENTER (10023900)

Y.C./	Steingard, "Adjunctive Clonazepam Treatment of Tic Symptoms in Children with Comorbid Tic Disorders and ADHD, J. Am. Acad. Child Adolesc. Psychiatry, 33:3, March/April, 1994
Y.C./	Swartz, "Tardive Psychopathology", Neuropsychobiology, 43:115-119, 1995.
Y.C./	Tirelli et al., "Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice", J. Pharmacol Exp. Ther., 273:7-15, 1995.
Y.C./	Trube, et al., "Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity" Epilepsia. 35:5 S62-S67, 1994
Y.C./	Tsai, et al., "Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated with Tardive Dyskinesia", Am J. Psychiatry 155:9, September, 1998.
Y.C./	Vale et al., "Amantadine for Dyskinesia Tarda", New Eng. J. Med., 284:673, 1971.
Y.C./	Van-Rekum et al., "N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury", Brian Inj. 9:49-53, 1995.
Y.C./	Waddington et al., "Cognitive Dysfunction in Chronic Schizophrenia Followed Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive Dyskinesia", Psychol Med, 26:681-688, 1996.
Y.C./	Wenk et al., "MK-801, Memantine and Amantadine Show Neuroprotective Activity in the Nucleus Basalis Magnocellularis", Eur. J. Pharmacol, 293:267-270, 1995.
Y.C./	Wilde, et al., "Acamprosate", Adis Drug Evaluation, 53:1038-1053, June, 1997.
Y.C./	Yassa, et al., "Plasma Magnesium in Chronic Schizophrenia", Int. Pharmacopsychiat. 14:57-64 (1979)
Y.C./	Ziemann, et al., "Decreased Motor Inhibition in Tourette's Disorder: Evidence From Transcranial Magnetic Stimulation", Am J Psychiatry, 154:1277-1284, 1997.

EXAMINER /Yong Chong/

DATE CONSIDERED 07/18/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.